neoplasms by histologic type

Showing 1 - 25 of 43

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Respiratory Tract Diseases, Tumors, Tumors by Histologic Type Trial run by the National Cancer Institute (NCI) (Bevacizumab)

Not yet recruiting
  • Respiratory Tract Diseases
  • +14 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Solid Tumor, Haematological Malignancy, Malignant Tumor Trial in United Kingdom (Alectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Solid Tumor, Haematological Malignancy, Malignancy Trial in United Kingdom (Entrectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Malignancy, Malignant Tumor, Lymphoproliferative Disorders Trial in United Kingdom (Atezolizumab)

Not yet recruiting
  • Malignancy
  • +8 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Cervical Intraepithelial Neoplasia Grade 2/3, Tumor Cervix, Carcinoma in Situ Trial in Milan (Self-Collecting Devices, In Vitro

Completed
  • Cervical Intraepithelial Neoplasia Grade 2/3
  • +5 more
  • Self-Collecting Devices
  • In Vitro Diagnostic Assays
  • Dublin, Ireland
  • +5 more
Jan 5, 2023

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Prostatic Tumors, Castration-Resistant, Tumors by Histologic Type, Tumors, Prostate Trial in United States (P-PSMA-101 CAR-T

Active, not recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • +16 more
  • Duarte, California
  • +9 more
Nov 15, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Glioma, Recurrence, Disease Attributes Trial (Vorasidenib)

Available
  • Glioma
  • +10 more
  • (no location specified)
Oct 19, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)

Recruiting
  • Leukemia
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +9 more
Sep 9, 2022

Dupuytren Contracture, Dupuytren's Disease, Contracture Trial (procedure, drug, other)

Not yet recruiting
  • Dupuytren Contracture
  • +11 more
  • Percutaneous needle fasciotomy
  • +2 more
  • (no location specified)
Jun 30, 2022

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)

Active, not recruiting
  • Multiple Myeloma
  • +19 more
  • CYNK-001
  • Denver, Colorado
  • +8 more
May 24, 2022

Tumors, Tumors, Glandular and Epithelial, Tumors by Histologic Type Trial in San Antonio (Entinostat, Placebo)

Completed
  • Neoplasms
  • +14 more
  • San Antonio, Texas
    The START Center for Cancer Care
Apr 21, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Bortezomib, Cyclophosphamide)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Athens, Greece
  • +5 more
Mar 28, 2022

Multiple Myeloma, Renal Impairment, Tumors, Plasma Cell Trial in Greece (Isatuximab, Pomalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • +7 more
  • Athens, Greece
  • +5 more
Mar 17, 2022

Lymphoma, Large B-Cell, Diffuse, Tumors by Histologic Type Trial in China (penpulimab, lenalidomide, Rituximab, Gemcitabine,

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Neoplasms by Histologic Type
  • penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
  • Hefei, Anhui, China
  • +3 more
Mar 3, 2022

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)

Active, not recruiting
  • Hodgkin Disease
  • +8 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
  • +1 more
Mar 2, 2022

Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic Trial in United States (Vigil, Irinotecan, Temozolomide)

Active, not recruiting
  • Ewing Sarcoma
  • +12 more
  • Vigil
  • +2 more
  • Little Rock, Arkansas
  • +16 more
Feb 9, 2022

Esophageal Squamous Cell Carcinoma, Esophageal Tumors, Esophageal Diseases Trial (Anlotinib HCl, TQB2450)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • +10 more
  • (no location specified)
Feb 19, 2022

Tumors, Tumors, Glandular and Epithelial, Tumors by Histologic Type Trial in San Antonio (Entinostat, Pembrolizumab)

Completed
  • Neoplasms
  • +13 more
  • San Antonio, Texas
    The START Center for Cancer Care
Jan 24, 2022

Lymphoma, Lymphoma, Mantle-Cell, Tumors by Histologic Type Trial (IM19 CAR-T cells, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Lymphoma
  • +4 more
  • IM19 CAR-T cells
  • +2 more
  • (no location specified)
Nov 30, 2021